< Back to search
Filter
1
Active & ResponsiveNew

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

for
Metastatic Urothelial Carcinoma,
Location: Spokane WA, Los Angeles CA
Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT07815665

Phase2, Phase3, Recruiting
Active & Responsive

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

for
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT04878029

Phase1, Recruiting
Active & Responsive

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Male

Age: 18+

Code: NCT01050504

Recruiting
Active & Responsive

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

for
Locally Advanced Urothelial Carcinoma,
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 18+

Code: NCT07048457

Phase2, Recruiting
Active & Responsive

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Scarborough ME, Worcester MA, Hartford CT, Norwalk CT,
Sponsor: Massive Bio, Inc.

Sex: All

Age: 0+

Code: NCT03452774

Recruiting

Interested in new metastatic urothelial cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

for
Triple Negative Breast Cancer, HER2-negative Breast Cancer,
Location: Fairfax VA, Orlando FL, Huntersville NC, Sarasota FL,
Sponsor: Dren Bio

Sex: All

Age: 18+

Code: NCT06999187

Phase1, Recruiting
New

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

for
Metastatic Bladder Cancer, Peripheral Neuropathy,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT07548476

Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for
Urothelial Cancer, Advanced/Metastatic Urothelial Cancer,
Location: Norwich CT, New York NY, Albany NY, Clifton Park NY,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07421700

Phase1, Phase2, Recruiting

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

for
Neuropathy, Urothelial Carcinoma,
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07390617

Recruiting

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

for
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Location: New York NY, Lake Success NY, New Brunswick NJ,
Sponsor: Generate Biomedicines

Sex: All

Age: 18+

Code: NCT07484022

Phase1, Recruiting

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

for
Metastatic Urothelial Carcinoma,
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 18+

Code: NCT07221942

Phase2, Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for
Locally Advanced Urothelial Carcinoma,
Location: Worcester MA, Lebanon NH, Stony Brook NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06524544

Phase3, Recruiting

Sacituzumab Govitecan Plus EV in Metastatic UC

for
Urothelial Cancer, Metastatic Urothelial Carcinoma,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04724018

Phase1, Phase2, Recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

for
Metastatic Urothelial Carcinoma,
Location: New York NY, Miami FL, Atlanta GA, Dallas TX,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06439836

Phase1, Recruiting
New

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

for
Locally Advanced Bladder Urothelial Carcinoma,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT07667335

Phase1, Phase2, Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

for
Urothelial Cancer
Location: New York NY, Montreal, Baltimore MD, Ottawa,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07106762

Phase2, Phase3, Recruiting

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

for
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors,
Location: Boston MA, New York NY, Houston TX, Austin TX,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07193511

Phase1, Phase2, Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for
Metastatic Solid Tumor, Recurrent Solid Tumor,
Location: Boston MA, New York NY, Cleveland OH, Grand Rapids MI,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06465069

Phase1, Recruiting

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

for
Metastatic Bladder Urothelial Carcinoma,
Location: Chicago IL, Orland Park IL
Sponsor: Northwestern University

Sex: All

Age: 18+

Code: NCT06630416

Phase2, Recruiting

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

for
Metastatic Bladder Urothelial Carcinoma,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07087860

Phase2, Recruiting